Vanda Pharmaceuticals VNDA
- Market cap
- $234.6M
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 1.0×
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- $229.3M
- +8% on a year ago
- Net margin
- n/m
- outside −100% to 100%
- Free cash flow yield
- −59.7%
Vanda Pharmaceuticals trades at 1.0× sales. Its trailing earnings are negative, so it has no PE. Revenue was $229.3M over the last twelve months, up 8% on a year earlier.
Charts
Financials
| Income statement | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $45.3M−30% | $47.5M−24% | $50.5M+10% | $47.7M+23% | $53.2M+18% | $50M+5% | $52.6M+4% | $56.3M+18% | $57.2M+8% | $51.7M+3% | $50.5M−4% | $69.8M+24% | |
| Cost of revenue | $3.5M−45% | $3.4M−28% | $2.7M−22% | $2.6M−17% | $2.6M−25% | $3.5M+2% | $2.7M+0% | $3M+16% | $3.8M+48% | $3.2M−10% | $3.6M+30% | $4.2M+41% |
| Gross profit | $41.8M−28% | $44M−24% | $47.7M+12% | $45.1M+26% | $50.6M+21% | $46.5M+6% | $49.9M+4% | $53.3M+18% | $53.4M+6% | $48.6M+4% | $47M−6% | $65.7M+23% |
| R&D | $24.3M+32% | $21.2M+10% | $16.7M+0% | $16.8M+1% | $19.8M−19% | $35.7M+69% | $22M+32% | $22.6M+35% | $29M+46% | $28.4M−20% | $37M+68% | $27.6M+22% |
| SG&A | $23.6M−28% | $30.1M−17% | $39.5M+39% | $37.6M+52% | $39.3M+66% | $50.1M+67% | $64.6M+64% | $60.3M+60% | $63M+60% | $68.4M+37% | $71.8M+11% | $59.6M−1% |
| −$7.1M | −$9.2M | −$10.1M+254% | −$11M+84% | −$10.3M+45% | −$41M+344% | −$38.5M+280% | −$31.3M+184% | −$40.4M+293% | −$50.2M+22% | −$63.8M+66% | −$23.5M−25% | |
| Pre-tax income | −$1.7M | −$4.7M | −$5.5M | −$6.2M+5103% | −$6.5M+291% | −$37.4M+701% | −$34.9M+533% | −$28.4M+355% | −$38M+485% | −$48.4M+30% | −$62.4M+79% | −$22.4M−21% |
| $739K−73% | −$518K | −$998K | −$920K+258% | −$1.6M | −$7.9M+1420% | −$7.7M+670% | −$5.8M+531% | $103.2M | $143K | $129K | $174K | |
| Net income | −$2.4M | −$4.1M | −$4.5M | −$5.3M | −$4.9M+105% | −$29.5M+611% | −$27.2M+502% | −$22.6M+324% | −$141.2M+2774% | −$48.6M+65% | −$62.5M+130% | −$22.6M−0% |
| −$0.04 | −$0.07 | −$0.08 | −$0.09 | −$0.08+100% | −$0.50+614% | −$0.46+475% | −$0.38+322% | −$2.39+2888% | −$0.82+64% | −$1.04+126% | −$0.37−3% | |
| 57.5M+1% | 57.8M+1% | 58.2M+1% | 58.3M+1% | 58.3M+1% | 58.5M+1% | 59M+1% | 59.1M+1% | 59.1M+1% | 59.5M+2% | 60.2M+2% | 60.5M+2% |
Gross profit: 53 periods, Q2 FY10 to Q3 FY26: not printed by the filing, worked out from its own lines.
EPS, diluted: 10 periods, Q4 FY10 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 5 periods, Q4 FY10 to Q4 FY21: share-days: the 12-month average less the 9-month, weighted by days. 9 periods, Q4 FY11 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. Q4 FY14 and Q4 FY22: the earlier year to date counted no dilution: the quarter's basic count plus the later year to date's dilution.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Drug Manufacturers - General nearest Vanda Pharmaceuticals' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| VNDAVanda Pharmaceuticals | $234.6M | n/m | 34.4× | 1.0× | +8% | n/m | |
| NATRNatures Sunshine Products | $211.5M | 11.9× | 20.2× | 0.4× | +7% | 3.7% | |
| CRMDCorMedix | $420.1M | 2.5× | 4.0× | 0.9× | +281% | 40.5% | |
| ARVNArvinas | $491.7M | 47.0× | 50.5× | 1.6× | −15% | 2.9% | |
| PBYIPuma Biotechnology | $525.5M | 19.6× | 12.3× | 2.3× | −3% | 11.6% | |
| IRWDIronwood Pharmaceuticals | $571.7M | 4.5× | 14.8× | 1.5× | +26% | 33.4% | |
| ZVRAZevra Therapeutics | $599.8M | 10.9× | 12.2× | 4.4× | +119% | 42.8% | |
| LFVNLifevantage | $73.5M | 14.7× | 19.4× | 0.4× | −20% | 2.8% | |
| COLLCollegium Pharmaceutical | $770.9M | 19.1× | 19.1× | 1.0× | +14% | 5.9% | |
| ABUSArbutus Biopharma | $791.4M | 5.1× | 5.6× | 4.4× | n/m | 84.2% | |
| SPROSpero Therapeutics | $60.6M | 9.5× | 9.5× | 1.3× | −3% | 15.7% | |
| Peer median | $508.6M | 11.4× | 13.5× | 1.4× | +7% | 13.6% |
More on Vanda Pharmaceuticals
Each number over time
- PE ratio
- Price to sales ratio
- EV/EBIT
- Price to free cash flow
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Its groups
About
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .